Drug
AGB101
AGB101 is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_2
3
100%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Terminated(1)
Detailed Status
Recruiting2
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 23 (100.0%)
Trials by Status
withdrawn133%
recruiting267%
Recent Activity
2 active trials
Showing 3 of 3
recruitingphase_2
Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults
NCT06919926
recruitingphase_2
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
NCT05824728
withdrawnphase_2
Clinical Trial of AGB101 for Mild Cognitive Impairment
NCT05986721
Clinical Trials (3)
Showing 3 of 3 trials
NCT06919926Phase 2
Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults
NCT05824728Phase 2
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
NCT05986721Phase 2
Clinical Trial of AGB101 for Mild Cognitive Impairment
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3